No results for ‘’
Godavari Drugs Ltd
₹101
(1%)
Tue, 25 Aug 2026, 10:09 pm
Health Technology
Pharmaceuticals: Major
24.5KGodavari Drugs Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 3.68 | 10.10 | 0 | 0 | 0 | 144.50 | 0 | 12.66 | 5.04 | 11.03 | 21.45 | 15.77 | 28.73 | 14.55 | 4.35 | 8.35 | 9.39 | 15.07 | 12.61 | 15.04 |
| Price to book ratio | 1.67 | 1.08 | 0.75 | 0.32 | 0.47 | 0.48 | 0.50 | 0.84 | 0.89 | 3.26 | 2.11 | 1.82 | 1.44 | 0.99 | 0.44 | 1.45 | 1.69 | 1.74 | 1.82 | 1.54 |
| Price to sales ratio | 4.71 | 2.67 | 1.81 | 0.80 | 0.98 | 0.83 | 0.97 | 0.80 | 0.84 | 0.73 | 0.41 | 0.38 | 0.37 | 0.21 | 0.09 | 0.28 | 0.31 | 0.36 | 0.45 | 0.58 |
| Price to cash flow ratio | 5.28 | 45.74 | 6.29 | 5.80 | 10.46 | 7.21 | 7.38 | 7.55 | 3.49 | 0 | 0 | 10.81 | 16.98 | 21.42 | 2.61 | 0 | 5.88 | 6.14 | 5.19 | 10.19 |
| Enterprise value | 20.1Cr | 14.51Cr | 9.25Cr | 4.92Cr | 5.73Cr | 5.54Cr | 5.57Cr | 8.22Cr | 9.79Cr | 48.43Cr | 43.78Cr | 43.38Cr | 40.36Cr | 38.12Cr | 34.87Cr | 63.27Cr | 70.05Cr | 89.8Cr | 125Cr | 128Cr |
| Enterprise value to EBITDA ratio | 0 | 536.11 | 36.96 | 6.66 | 6.60 | 5.43 | 0 | 3.99 | 4.26 | 7.95 | 9.69 | 8.25 | 9.99 | 6.96 | 5.78 | 6.44 | 6.17 | 7.37 | 9.21 | 10.43 |
| Debt to equity ratio | 0.92 | 0.41 | 0.23 | 0.21 | 0.17 | 0.15 | 0.29 | 0.33 | 0.27 | 0.69 | 1.13 | 1.01 | 1.10 | 1.25 | 1.40 | 1.28 | 0.79 | 1.09 | 1.50 | 1.50 |
| Return on equity % | 0 | 11.29 | -8.12 | -2.84 | -2.16 | 0.31 | -19.61 | 6.67 | 19.35 | 34.51 | 10.38 | 12.32 | 5.16 | 7.07 | 10.69 | 18.96 | 19.82 | 12.22 | 15.57 | 10.79 |
Godavari Drugs Ltd Price to Sales Ratio
The Godavari Drugs Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Godavari Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Godavari Drugs Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Godavari Drugs Ltd (NSE: , BSE: 530317) is currently trading at ₹101, with a market capitalization of ₹102.29Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Godavari Drugs Ltd Price to Sales Ratio is essential for fundamental analysis.
Godavari Drugs Ltd Price to Sales Ratio Current Value
The current Godavari Drugs Ltd Price to Sales Ratio stands at 0.58.
The latest Godavari Drugs Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Godavari Drugs Ltd Price to Sales Ratio Historical Trend
The Godavari Drugs Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 0.58
- 2023: 0.45
- 2022: 0.36
- 2021: 0.31
- 2020: 0.28
The recent rise in Godavari Drugs Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Godavari Drugs Ltd Price to Sales Ratio Indicates for Investors
The Godavari Drugs Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Godavari Drugs Ltd Price to Sales Ratio Analysis Summary
The Godavari Drugs Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Godavari Drugs Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Godavari Drugs Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.